Is alendronate effective to treat bone loss in renal transplantation recipients?
At least in the short term, alendronate is a effective inhibitor for the treatment of bone loss in renal transplantation patients.
Patients with hospital-acquired PFF have poor outcomes. Adequate supervision, provision of hip protectors in the hospital, and strategies that address fracture circumstances may hold the keys to prevention.